Aperture Health Acquires Triad Therapeutics [Professional Services Close – Up]

Aperture Health, Inc. announced that it has completed the acquisition of Triad Therapeutics, Inc., a homecare infusion therapy and nursing provider in New Jersey serving the tri-state area.

The Company noted, as a result, Triad has become a subsidiary of Aperture Health, Inc., and will remain as the operating company for the combined business.

Triad provides specialized home healthcare services to patients requiring intravenous therapy including antibiotics, pain management, hydration, immunoglobulins, steroids, total nutritional solutions, and IV catheter insertions and maintenance. The Company provides a complete solution to patients including the preparation and delivery of sterile compounded IV medications, supplies and equipment, along with specialized nursing care and teaching of the patient and/or caregivers on the administration of therapies as prescribed by a physician.

Triad is a fully JCAHO accredited home IV therapy company, achieving this "gold standard" status in 2007. The company has built a well respected reputation in its industry for its therapy expertise and commitment to care for its patient clients. The company services clients throughout the states of New Jersey, New York and Connecticut, providing opportunity for organic growth. Triad's full time marketing and sales personnel continuously represent the company in the core services areas, growing and maintaining the company's referral source base. Patient referrals are made from physicians, hospitals, insurance companies, veterinarians and hospice care providers that have established a professional rapport with Triad.

All patient clients accepted to Triad's service have been preapproved for care by the client's health insurance provider. Triad maintains numerous managed care service provider contracts, many of which are part of "closed networks," thus provide strong barriers to entry in the industry.

James Hennig, R.Ph, Chief Executive Officer and Chairman of the Board of Directors said, "We are very pleased to become a U.S. publicly listed company which will contribute to our market awareness and provide a platform for the capital necessary for us to implement our growth strategy which includes acquisitions and other joint ventures, as well as, organic growth through new referral sources and product and service enhancements."

((Comments on this story may be sent to [email protected]))